

Special Issue

Novel Therapeutic Approaches for Lyme Disease

Message from the Guest Editor

Lyme disease is the number one vector-borne illness in the United States caused by *Borrelia burgdorferi* sensu lato species and transmitted via the bite of Ixodes species. The frontline treatment for Lyme disease is the administration of antibiotics such as doxycycline, minocycline, amoxicillin, cefuroxime, and ceftriaxone. Although treatment of early Lyme disease is generally successful, studies have shown that some patients are not successfully treated and go on to develop persistent Lyme disease symptoms. One of the possible explanations for this clinical observation is the presence of different morphological forms of *B. burgdorferi*, such as round bodies, persisters, and biofilms with differences in sensitivity to antibiotics. While recent *in vitro* studies have suggested novel antimicrobial agents and their combinations to combat these resistant forms, there is still an urgent need to find a therapeutic treatment for Lyme disease whose effectiveness can be proven clinically. This Special Issue seeks manuscript submissions for novel therapeutic approaches for Lyme disease, such as original research papers, short communications, reviews, case reports, and perspectives.

Guest Editor

Prof. Dr. Eva Sapi
Department of Biology and Environment Science, University of New Haven, West Haven, CT 06516, USA

Deadline for manuscript submissions

closed (30 June 2023)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/130203

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)